Adaptin Bio, Inc. (APTN): R&D Expense
$1.77M
Year ended 2025-12-31
$1.68M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.77M | -2.8% | 2026-04-01, From 2025-01-01 |
| 2024-12-31 | $1.82M | n/a | 2026-04-01, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Adaptin Bio, Inc. (APTN) | 2025-12-31 | $1.77M | -2.8% |
| Liminatus Pharma, Inc. (LIMN) | 2024-12-31 | $2.69M | n/a |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 2025-12-31 | $4.17M | -10.2% |
| Abpro Holdings, Inc. (ABPO) | 2025-12-31 | $989.0K | -66.8% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $100.0K | -39.0% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $3.13M | +127.7% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $10.25M | n/a |
| BioCardia, Inc. (BCDA) | 2025-12-31 | $4.96M | +13.1% |
| Tevogen Inc. (TVGN) | 2025-12-31 | $11.11M | -64.2% |
Compare APTN, LIMN, BCLI, ABPO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗